Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ramsey Baghdadi

Ramsey Baghdadi covered regulation, reimbursement, and legislative policy for over a decade as Editor-in-Chief of The RPM Report and a contributing editor to Pink Sheet. He previously served as managing editor for the OTC drug and dietary supplement industry publication The Tan Sheet. Prior to his work in the drug sector, he covered the medical device industry as financial editor of The Gray Sheet.

Latest From Ramsey Baghdadi

Are Regulators Ready For The Robot Era? ChatGPT Weighs In On EU Regulation

Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.

Artificial Intelligence FDA

ICER Hemophilia Gene Therapy Reviews Show Clear ‘Net Health Benefit’ But Caution On Patient, Payer Fronts Given Upfront Costs

Restrictive interpretations of FDA labels for BioMarin and CSL Behring products by payers could signal slow launch of gene therapies seeking to supplant existing treatments.

Gene Therapy Health Technology Assessment

Accelerated Approval For Gene Therapies: FDA’s Wilson Bryan Offers A ‘Framework’

Bryan, who oversees reviews of gene and cell therapies in US FDA’s biologics center, cautioned against falling in love with a biomarker when it is showing no ‘clinical effect.’

Gene Therapy Review Pathway

Drug Pricing And User Fees: CBER Will Need To Build Up As Gene Therapies Become More Popular

A quickened shift toward gene therapies for small populations may be the result of the new Medicare drug pricing law given protections afforded to those types of products.

United States BioPharmaceutical

US FDA’s ALS Science Strategy Includes Near-Term Rare Neurodegenerative Disease Task Force

Five-year plan includes multi-phased approach to ALS at the same time that Amylyx’s AMX0035 is pending review with a late September decision deadline; action plan’s mid-term priorities for FY 2023-2024 include a cell and gene therapies safety project.

Drug Approval Standards Rare Diseases

Senate Commerce Leaders Want An FTC Study Into PBM Business Practices – And More

Committee Chair Maria Cantwell (D-Wash.) solicits advice from witnesses for additional authorities to conduct oversight of PBMs and pushes for a GAO study.

Pricing Debate Policy
See All
UsernamePublicRestriction

Register